Vistagen CEO to Present at RBC Healthcare Conference Amid Key Clinical Trials
Event summary
- Vistagen CEO Shawn Singh to participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026.
- Company will host one-on-one meetings during the conference.
- Live webcast available on Vistagen’s Investors section, with replay archived post-event.
- Vistagen’s lead candidates include fasedienol (Phase 3 for social anxiety disorder), itruvone (major depressive disorder), and refisolone (menopause symptoms).
The big picture
Vistagen’s participation in the RBC conference comes as it advances multiple late-stage neuroscience candidates, a high-stakes period for biopharma companies seeking to validate novel delivery mechanisms. The focus on intranasal pherines—designed to bypass systemic absorption—positions Vistagen in a niche but growing segment of rapid-onset therapeutics. Success hinges on clinical outcomes and investor perception of its differentiated approach.
What we're watching
- Clinical Milestones
- The pace at which Vistagen advances its Phase 3 candidate fasedienol will determine near-term investor sentiment.
- Market Positioning
- Whether Vistagen can differentiate its intranasal pherines in a competitive neuroscience landscape.
- Investor Sentiment
- How CEO Shawn Singh’s conference messaging impacts confidence in Vistagen’s execution strategy.